<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545662</url>
  </required_header>
  <id_info>
    <org_study_id>BA-HD042</org_study_id>
    <secondary_id>HD042687-04</secondary_id>
    <secondary_id>HD042738-05</secondary_id>
    <secondary_id>HD042678-03</secondary_id>
    <secondary_id>HD042653-05</secondary_id>
    <secondary_id>HD042689-05</secondary_id>
    <secondary_id>HD042736-04</secondary_id>
    <secondary_id>HD 042686-01A1</secondary_id>
    <secondary_id>HD042652-04</secondary_id>
    <secondary_id>HD042823-05</secondary_id>
    <nct_id>NCT00545662</nct_id>
  </id_info>
  <brief_title>Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)</brief_title>
  <acronym>COBRIT</acronym>
  <official_title>Citicoline Brain Injury Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Citicoline Brain Injury Treatment (COBRIT) is a randomized, double-blind, placebo
      controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome
      in patients with complicated mild, moderate and severe traumatic brain injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traumatic brain injury (TBI) is a major cause of death and disability. In the United States
      alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over
      200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy
      for the treatment of TBI has been established in either the acute or post acute setting.
      Citicoline is a naturally occurring endogenous compound. This compound offers the potential
      of employing neuroprotection, neuro-recovery and neurofacilitation to enhance recovery after
      TBI.

      The primary goal of this study is to assess the efficacy of citicoline compared to placebo on
      functional and cognitive outcome in participants with traumatic brain injury.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial stopped due to futility.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional and Cognitive Outcome</measure>
    <time_frame>90 days</time_frame>
    <description>The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&amp;2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE&gt;7, CVLT&gt;36, PSI&gt;85, TMT part A &lt;42, TMT part B&lt;138.1, DS&gt;7.15, ST1&lt;60.29, ST2&lt;151.47, COWAT&gt;32.5. Logistic regression was used to estimate the global OR.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1213</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo tablets formulated to resemble the citicoline treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citicoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citicoline</intervention_name>
    <description>1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.</description>
    <arm_group_label>Citicoline</arm_group_label>
    <other_name>CDP-Choline, Cytidine 5-diphosphocholine, Somazina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-penetrating traumatic brain injury.

          2. Age 18 (19 in Alabama) - 70 years.

          3. GCS criteria on/off paralytics as specified in protocol

          4. Reasonable expectation of completion of outcomes measures at a network center at six
             months post-injury.

          5. Able to swallow oral medication or, if unable to swallow, a gastric tube or peg are
             placed by 23 hours after injury.

          6. Reasonable expectation of enrollment within 24-hour time window.

          7. English-speaking

        Exclusion Criteria:

          1. Intubated patients with GCS motor score = 6 and not meeting CT criteria.

          2. Bilaterally fixed and dilated pupils

          3. Positive pregnancy test, known pregnancy, or currently breast feeding

          4. Evidence of diseases that interfere with outcome assessment

          5. Current acetylcholinesterase inhibitor use (Appendix 1)

          6. Imminent death or current life-threatening disease

          7. Currently enrolled in another study

          8. Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry Melton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Eisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Jallo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Ricker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelly Timmons, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Diaz-Arrastia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Temkin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beth Ansel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Friedewald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Department of Biostatistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141-3099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Sciences Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>23298-0631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <results_first_submitted>November 29, 2011</results_first_submitted>
  <results_first_submitted_qc>November 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2012</results_first_posted>
  <last_update_submitted>November 16, 2012</last_update_submitted>
  <last_update_submitted_qc>November 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>William Friedewald</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>cognition</keyword>
  <keyword>behavioral outcome</keyword>
  <keyword>functional outcome</keyword>
  <keyword>treatment</keyword>
  <keyword>early intervention</keyword>
  <keyword>citicoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant were recruited from eight level I trauma centers: Virginia Commonwealth University; University of Maryland; Temple University; University of Tennessee; University of Alabama (Birmingham); University of Texas Southwestern (Dallas); University of Pittsburgh; University of Washington. Recruitment began on 7/23/2007 and ended on 2/4/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>The first dose of placebo was administered within 24 hours of traumatic brain injury. Placebo was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
        <group group_id="P2">
          <title>Treatment</title>
          <description>Treatment with citicoline begun within 24 hours of traumatic brain injury. Treatment was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="606"/>
                <participants group_id="P2" count="607"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="521"/>
                <participants group_id="P2" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>The first dose of placebo was administered within 24 hours of traumatic brain injury. Placebo was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
        <group group_id="B2">
          <title>Treatment</title>
          <description>Treatment with citicoline begun within 24 hours of traumatic brain injury. Treatment was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="606"/>
            <count group_id="B2" value="607"/>
            <count group_id="B3" value="1213"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="563"/>
                    <measurement group_id="B3" value="1131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="15.5"/>
                    <measurement group_id="B2" value="39.7" spread="16.2"/>
                    <measurement group_id="B3" value="40.4" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="607"/>
                    <measurement group_id="B3" value="1213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional and Cognitive Outcome</title>
        <description>The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&amp;2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE&gt;7, CVLT&gt;36, PSI&gt;85, TMT part A &lt;42, TMT part B&lt;138.1, DS&gt;7.15, ST1&lt;60.29, ST2&lt;151.47, COWAT&gt;32.5. Logistic regression was used to estimate the global OR.</description>
        <time_frame>90 days</time_frame>
        <population>The analysis included both the patients with complete outcome data and those with at least one measure. Patients who died were also included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The first dose of placebo was administered within 24 hours of traumatic brain injury. Placebo was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
          </group>
          <group group_id="O2">
            <title>Treatment</title>
            <description>Treatment with citicoline begun within 24 hours of traumatic brain injury. Treatment was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional and Cognitive Outcome</title>
          <description>The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&amp;2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE&gt;7, CVLT&gt;36, PSI&gt;85, TMT part A &lt;42, TMT part B&lt;138.1, DS&gt;7.15, ST1&lt;60.29, ST2&lt;151.47, COWAT&gt;32.5. Logistic regression was used to estimate the global OR.</description>
          <population>The analysis included both the patients with complete outcome data and those with at least one measure. Patients who died were also included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glasgow Outcome Scale - Extended</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56"/>
                    <measurement group_id="O2" value="35.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>California Verbal Learning Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.48"/>
                    <measurement group_id="O2" value="57.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Processing Speed Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.28"/>
                    <measurement group_id="O2" value="52.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.96"/>
                    <measurement group_id="O2" value="64.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.05"/>
                    <measurement group_id="O2" value="74.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digit Span</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.02"/>
                    <measurement group_id="O2" value="86.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroop Task 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.95"/>
                    <measurement group_id="O2" value="65.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroop Task 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.59"/>
                    <measurement group_id="O2" value="68.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controlled Oral Word Association Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.68"/>
                    <measurement group_id="O2" value="37.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The placebo and citicoline groups do not differ at 90-days on the Core Battery
Power:
Two sided type I error of 0.05
85% power
Expected OR=1.40 for the global statistic
Response rate in the control group
Correlations among the nine measures were accounted for. Response rates for the whole sample were a weighted average of the rates provided by TBI severity.
1240 participants were required to detect an OR &gt;= 1.4 for the global statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>a priori threshold for statistical significance is 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression estimated global OR. GEE accounted for correlations of the scales. Models adjusted for site &amp; injury severity.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>The odds in the citicoline group were compared to the odds in the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>The first dose of placebo was administered within 24 hours of traumatic brain injury. Placebo was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
        <group group_id="E2">
          <title>Treatment</title>
          <description>Treatment with citicoline begun within 24 hours of traumatic brain injury. Treatment was administered orally or enterally depending upon whether the participant could swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Excretory/Urinary</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="452" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="449" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ophthalmologic</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever/Infection</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="308" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic/Skin</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="606"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Friedewald</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-3017</phone>
      <email>wtf1@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

